RankAlpha logo
Back to Rankings

EDIT

Editas MedicineC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
The constructive case is that Editas has sharpened into a single lead in vivo program, reiterated a mid-2026 IND/CTA path, still targets first-in-human initiation later in 2026, and had previously guided cash runway into the third quarter of 2027 before the late-May financing, which should extend flexibility further [#SEC-8K-2026-03-09] [#SEC-8K-2026-05-05] [#8-K-2026-05-26].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +23.8.
What can break
Clinical and regulatory execution risk remains high as the company transitions EDIT-401 from preclinical work into first-in-human testing.
Momentum
85
Value
41
Sentiment
43
Setup hits (3d)
— · Net —
AI TargetsBase $2.80 · Bull $4.50 · Bear $1.40
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-12 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net —
Target $5.78
Why
Momentum85 · Δ7d +23.8
Value41 · Δ7d -0.1
Sentiment43 · Δ7d +13.8
So what
Balanced signals. Wait for confirmation before sizing up.
Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits
Lead driver: Momentum · See technicals
Momentum
85
26% active weight
Current posture
7d trendImproving
Δ7d
+23.8
Δ21d
-0.1
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
43
34% active weight
Current posture
7d trendImproving
Δ7d
+13.8
Δ21d
-2.6
Why this grade

Composite grade C. Momentum 84.6 / Value 41.1 / Sentiment 43.0

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$457.32M
Beta
2.15
Shares Out
153.46M
P/E (TTM) · Derived
-1.7
P/S (TTM)
4.19
P/FCF (TTM) · Derived
-1.92
Rev YoY
-39.2%
EPS YoY
-72.1%
Gross Margin
+90.1%
Op Margin
-428.7%
Net Debt
-$69.94M
Current Ratio
3.22
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology